Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JCE7 | ISIN: US4161962026 | Ticker-Symbol: HHK1
Frankfurt
27.01.25
08:11 Uhr
4,800 Euro
-0,250
-4,95 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
HARTE-HANKS INC Chart 1 Jahr
5-Tage-Chart
HARTE-HANKS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,0005,15018:09
ACCESS Newswire
697 Leser
Artikel bewerten:
(2)

Harte Hanks, Inc.: Harte Hanks and Outreach Team Up to Deliver Innovative Sales Engagement Solutions

Finanznachrichten News

CHELMSFORD, MA / ACCESSWIRE / August 19, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), the 101-year-old Massachusetts-based global customer experience company, today announced it is collaborating with Outreach, a best-in-class execution platform built for intelligent revenue workflows. By working together each company will join to bring customers enhanced turnkey sales solutions. Through this cooperation agreement, Harte Hanks and Outreach will integrate their strengths with one goal: to deliver superior customer relationship management and end-user customer experiences. Together the two companies will leverage joint marketing initiatives and co-branded campaigns to reach a wider audience.

Harte Hanks will use the Outreach platform to engage customers and build additional sales pipeline. The Company will embed Outreach into its newly released Demand Generation in a Box product to help clients streamline and improve sales efforts. Aligning with Outreach gives Harte Hanks a competitive edge.

"We are excited to join forces with Outreach to empower our delivery teams to accelerate sales and drive meaningful business outcomes for our clients. Together, we can offer our clients an unmatched combination of strategic expertise and cutting-edge technology to drive their sales success" noted Varsha Tomar, Vice President of Partnerships at Harte Hanks.

Revenue teams of all sizes use Outreach to design, measure, and improve seller workflows. Powered by AI built on the largest foundation of direct sales data, Sales, RevOps, and Account Management leaders use Outreach to cut through the noise and create structured, aligned repeatable go-to-market processes. The platform improves the efficiency and effectiveness of every sales workflow, including prospecting and managing accounts, closing new business, expansion opportunities and renewals, rep coaching, and forecasting.

"Outreach looks for world-class partners that are leaders in their field, and we're thrilled to partner with Harte Hanks to deliver a premium experience to our customers." Added Dick O'Hara, Senior Director, Global Channel Sales, of Outreach. "Together, we will empower sales professionals to unlock success for themselves and their organization."

About Outreach

Outreach is a best-in-class Sales Execution Platform built for intelligent revenue workflows. Built on the world's largest foundation of customer interactions and go-to-market team data, Outreach gives teams the tools they need to design, execute, and continuously improve a revenue strategy that is disciplined, achievable, and optimized for every stage of the customer journey. The world's most effective revenue organizations, including Cisco, Okta, SAP, Siemens, and Verizon, use Outreach to power workflows, put customers at the center of their business, and win in the market. Outreach is a privately held company based in Seattle, Washington, with offices worldwide. To learn more, please visit www.outreach.io.

About Harte Hanks:

Harte Hanks (NASDAQ:HHS) is a leading global customer experience company whose mission is to partner with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.

Using its unparalleled resources and award-winning talent in the areas of Customer Care, Fulfillment and Logistics, and Marketing Services, Harte Hanks has a proven track record of driving results for some of the world's premier brands, including GlaxoSmithKline, Unilever, Pfizer, Max, Volvo, Ford, FedEx, Midea, and IBM among others. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,000 employees in offices across the Americas, Europe, and Asia Pacific.

For more information, visit hartehanks.com.

As used herein, "Harte Hanks" or "the Company" refers to Harte Hanks, Inc. and/or its applicable operating subsidiaries, as the context may require. Harte Hanks' logo and name are trademarks of Harte Hanks.

Cautionary Note Regarding Forward-Looking Statements:

Certain statements discussed in this release as well as in other reports, materials and oral statements that the Company releases from time to time to the public may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, words such as "anticipate," "estimate," "expect," "project," "intend," "believe," "plan," "target," "forecast" and similar expressions are intended to identify forward- looking statements. Such forward-looking statements concern management's expectations, strategic objectives, business prospects, anticipated economic performance and financial condition and other similar matters. Forward-looking statements are inherently uncertain and subject to a variety of assumptions, risks and uncertainties that could cause actual results to differ materially from those anticipated or expected by the management of the Company. These statements are not guarantees of future performance and actual events or results may differ significantly from these statements. Given these risk factors, investors and analysts should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of the document in which they are made. The Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which the forward-looking statement is based, except as required by law. It is advisable, however, to consult any further disclosures the Company makes in its filings with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K (if any). These statements constitute the Company's cautionary statements under the Private Securities Litigation Reform Act of 1995.

For media inquiries or further information, please contact: Jen.London@hartehanks.com

SOURCE: Harte Hanks, Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.